Skip to main content

Table 1 Patient and specimen characteristics

From: Comparative evaluation of the new FDA approved THxID™-BRAF test with high resolution melting and sanger sequencing

Characteristics

No.

%

Sex

  

  Male

67

59.3

  Female

46

40.7

Melanoma type

  

  Primary

41

36.3

  Metastatic:

72

63.7

   Node

24

33.3

   Skin

23

31.9

   Brain

7

9.7

   Lung

5

6.9

   Eye

4

5.6

   Liver

3

4.2

   Others (intestine, bone, etc.)

6

8.3

Average age (years)

63.2

 

Sample type

  

  Slide

36

31.9

   Tissue surface mean (mm2)

97.2

 

   [DNA] (ng/μl)

38.7

 

  Punch

77

68.1

   Tissue volume mean (mm3)

1.02

 

   [DNA] (ng/μl)

266

 

Tumor cell content 1

  

  <80%

12

10.6

  >80%

101

89.4

Melanin rate

  

  Sample 0

105

92.9

  Sample + (5 to 15%)

5

4.4

  Sample ++ (20 to 45%)

2

1.8

  Sample +++ (>50%)

1

0.9

Necrosis rate

  

  Sample 0

92

81.4

  Sample + (<10%)

15

13.3

  Sample ++ to +++ (>10%)

6

5.3

  1. 1After macro-dissection, when applicable.